Biocryst Pharmaceuticals (BCRX) To Announce Results From The BCX4161 Opus-1 Phase 2 Trial For Hereditary Angioedema May 27
5/27/2014 8:57:14 AM
RESEARCH TRIANGLE PARK, N.C., May 24, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) today announced that management plans to report results for the OPuS-1 (Oral ProphylaxiS-1) proof of concept Phase 2a clinical trial of orally-administered BCX4161 in patients with hereditary angioedema (HAE) the morning of Tuesday, May 27, 2014. BioCryst will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the trial results.
Help employers find you! Check out all the jobs and post your resume.
comments powered by